The company manufactures and sells cement and clinker, primarily serving the infrastructure and housing sectors in Southern India. It operates as a subsidiary of Sagar Cements Limited following a court-approved insolvency resolution process.
The company lacks a durable moat as evidenced by persistent net losses and negative interest coverage. While it has a regional presence, it operates in a highly cyclical and commodity-driven industry where it lacks the scale or cost advantage to maintain profitability during market downturns.
Capital allocation is currently focused on survival and catch-up CAPEX, specifically a modernization project to increase capacity and fuel efficiency. The company relies heavily on inter-corporate deposits and financial support from its parent company, Sagar Cements, to fund operations and expansion.
The modernization project failed to offset the crushing weight of a 13x debt-to-equity ratio, leading to a liquidity trap where interest obligations consumed all operating cash flow. As the parent company, Sagar Cements, prioritized its own balance sheet during a cyclical downturn, the promised synergies vanished and the merger terms disadvantaged minority shareholders. The reliance on deferred tax assets proved illusory as the company never generated the taxable profits required to realize them, resulting in a massive write-down of net worth and eventual insolvency.
RichFakir rates Andhra Cements Ltd's business quality as poor — 21/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Andhra Cements Ltd is trading about 47% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Andhra Cements Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Andhra Cements Ltd's fair value is about ₹67 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →